V S Mitrofanov

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Tests were set up on rats, guinea pigs and dogs to look into the cronic toxicity of nonachlazine, an effective antianginal agent, used for a space of 6 months in doses of 10 and 35 mg/kg, by far superior to the ones effectively employed clinically. The results of hematological, morphological and biochemical investigations bear evidence to a low toxicity of(More)
The results obtained by a study of acute and chronic toxicity of nonachlazine--a new original coronary-active agent endowed with antianginal properties are reported. Nonachlazine has been found to have a sufficiently wide range of therapeutic action. With its repeated (for 36 days) oral introduction to rats in an effective dose of 10 mg/kg the drug does not(More)
The base of current management of bronchopulmonary aspergillosis with allergic manifestations (BPAAM) is glucocorticosteroid treatment. These hormones are introduced in a mean dose 0.5 mg/kg (by prednisolone) to correct bronchial obstruction, reduce eosinophilia and resolve (completely or partially) infiltrates in the lungs. This being achieved, the dose is(More)
Five patients (4 men and 1 woman) afflicted with bronchopulmonary aspergillosis (ABPA) were examined. The main criteria for the diagnosis were a high level of the total IgE, demonstration of specific IgE to Aspergillus fumigatus, positive skin tests with antigens of moldy fungi. All the 4 patients with active process, not given corticosteroids, manifested(More)
Nonachlazine infused in the form of a solution penetrates rapidly the blood and organs. In experiments on cats it was shown that infusion of the drug into the stomach enriches the speed of blood flow and oxyhemoglobin amount in the coronary sinus blood after 2--3 minutes. Heart oxygen consumption increases slightly. Nonachlazine solution is little toxic. As(More)